nodes	percent_of_prediction	percent_of_DWPC	metapath
Galantamine—CHRFAM7A—corpus luteum—ovarian cancer	0.0467	0.133	CbGeAlD
Galantamine—CHRNA7—corpus luteum—ovarian cancer	0.0377	0.107	CbGeAlD
Galantamine—CHRFAM7A—ovarian follicle—ovarian cancer	0.0365	0.104	CbGeAlD
Galantamine—CHRNA7—ovarian follicle—ovarian cancer	0.0295	0.0838	CbGeAlD
Galantamine—CHRNA9—embryo—ovarian cancer	0.0198	0.0563	CbGeAlD
Galantamine—BCHE—diaphragm—ovarian cancer	0.0193	0.0547	CbGeAlD
Galantamine—CHRNG—myometrium—ovarian cancer	0.0107	0.0305	CbGeAlD
Galantamine—CHRNE—testis—ovarian cancer	0.0101	0.0287	CbGeAlD
Galantamine—CHRNA5—vagina—ovarian cancer	0.00793	0.0225	CbGeAlD
Galantamine—CHRNA5—testis—ovarian cancer	0.00708	0.0201	CbGeAlD
Galantamine—CHRNB2—myometrium—ovarian cancer	0.00655	0.0186	CbGeAlD
Galantamine—CHRNG—bone marrow—ovarian cancer	0.00591	0.0168	CbGeAlD
Galantamine—CHRNA5—lymph node—ovarian cancer	0.00513	0.0146	CbGeAlD
Galantamine—CHRNB2—uterine cervix—ovarian cancer	0.00509	0.0145	CbGeAlD
Galantamine—CHRNB4—testis—ovarian cancer	0.00487	0.0138	CbGeAlD
Galantamine—CHRNB2—decidua—ovarian cancer	0.00485	0.0138	CbGeAlD
Galantamine—CHRNA10—vagina—ovarian cancer	0.00481	0.0136	CbGeAlD
Galantamine—CHRNB2—endometrium—ovarian cancer	0.00461	0.0131	CbGeAlD
Galantamine—CHRNA10—testis—ovarian cancer	0.00429	0.0122	CbGeAlD
Galantamine—CHRNB1—uterine cervix—ovarian cancer	0.00427	0.0121	CbGeAlD
Galantamine—CHRNB2—uterus—ovarian cancer	0.00425	0.0121	CbGeAlD
Galantamine—CHRNB2—bone marrow—ovarian cancer	0.0036	0.0102	CbGeAlD
Galantamine—CHRNB2—female gonad—ovarian cancer	0.00347	0.00986	CbGeAlD
Galantamine—CHRNB2—vagina—ovarian cancer	0.00345	0.0098	CbGeAlD
Galantamine—CHRNA10—lymph node—ovarian cancer	0.00311	0.00883	CbGeAlD
Galantamine—CHRNB2—testis—ovarian cancer	0.00308	0.00875	CbGeAlD
Galantamine—CHRFAM7A—female reproductive system—ovarian cancer	0.00299	0.0085	CbGeAlD
Galantamine—CHRNA3—testis—ovarian cancer	0.00299	0.00848	CbGeAlD
Galantamine—CHRNB1—female gonad—ovarian cancer	0.00291	0.00827	CbGeAlD
Galantamine—CHRNB1—vagina—ovarian cancer	0.0029	0.00822	CbGeAlD
Galantamine—CHRFAM7A—female gonad—ovarian cancer	0.00272	0.00774	CbGeAlD
Galantamine—CHRNA7—uterus—ovarian cancer	0.00269	0.00764	CbGeAlD
Galantamine—CHRNB1—testis—ovarian cancer	0.00258	0.00734	CbGeAlD
Galantamine—CHRNA7—female reproductive system—ovarian cancer	0.00242	0.00687	CbGeAlD
Galantamine—CHRFAM7A—testis—ovarian cancer	0.00242	0.00686	CbGeAlD
Galantamine—BCHE—myometrium—ovarian cancer	0.00234	0.00665	CbGeAlD
Galantamine—ACHE—testis—ovarian cancer	0.00224	0.00636	CbGeAlD
Galantamine—CHRNB2—lymph node—ovarian cancer	0.00223	0.00634	CbGeAlD
Galantamine—CHRNA7—female gonad—ovarian cancer	0.0022	0.00625	CbGeAlD
Galantamine—CHRNA3—lymph node—ovarian cancer	0.00217	0.00615	CbGeAlD
Galantamine—CHRNA7—testis—ovarian cancer	0.00195	0.00554	CbGeAlD
Galantamine—CHRNB1—lymph node—ovarian cancer	0.00187	0.00532	CbGeAlD
Galantamine—BCHE—uterine cervix—ovarian cancer	0.00182	0.00517	CbGeAlD
Galantamine—BCHE—endometrium—ovarian cancer	0.00165	0.00468	CbGeAlD
Galantamine—ACHE—lymph node—ovarian cancer	0.00162	0.00461	CbGeAlD
Galantamine—BCHE—uterus—ovarian cancer	0.00152	0.00431	CbGeAlD
Galantamine—BCHE—female reproductive system—ovarian cancer	0.00136	0.00388	CbGeAlD
Galantamine—BCHE—bone marrow—ovarian cancer	0.00129	0.00366	CbGeAlD
Galantamine—BCHE—vagina—ovarian cancer	0.00123	0.0035	CbGeAlD
Galantamine—BCHE—testis—ovarian cancer	0.0011	0.00313	CbGeAlD
Galantamine—CYP3A4—female reproductive system—ovarian cancer	0.000919	0.00261	CbGeAlD
Galantamine—CYP2D6—female reproductive system—ovarian cancer	0.000904	0.00257	CbGeAlD
Galantamine—CYP2D6—female gonad—ovarian cancer	0.000823	0.00234	CbGeAlD
Galantamine—BCHE—lymph node—ovarian cancer	0.000798	0.00227	CbGeAlD
Galantamine—CYP2D6—testis—ovarian cancer	0.00073	0.00207	CbGeAlD
Galantamine—Skin disorder—Paclitaxel—ovarian cancer	0.000524	0.00104	CcSEcCtD
Galantamine—Bronchitis—Epirubicin—ovarian cancer	0.000522	0.00103	CcSEcCtD
Galantamine—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000522	0.00103	CcSEcCtD
Galantamine—Anaemia—Docetaxel—ovarian cancer	0.000518	0.00102	CcSEcCtD
Galantamine—Anorexia—Paclitaxel—ovarian cancer	0.000515	0.00102	CcSEcCtD
Galantamine—Gastritis—Doxorubicin—ovarian cancer	0.000514	0.00102	CcSEcCtD
Galantamine—Muscular weakness—Doxorubicin—ovarian cancer	0.000512	0.00101	CcSEcCtD
Galantamine—Vomiting—Vinorelbine—ovarian cancer	0.00051	0.00101	CcSEcCtD
Galantamine—Rash—Vinorelbine—ovarian cancer	0.000506	0.000999	CcSEcCtD
Galantamine—Dermatitis—Vinorelbine—ovarian cancer	0.000506	0.000998	CcSEcCtD
Galantamine—Hypotension—Paclitaxel—ovarian cancer	0.000504	0.000996	CcSEcCtD
Galantamine—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000504	0.000996	CcSEcCtD
Galantamine—Headache—Vinorelbine—ovarian cancer	0.000503	0.000993	CcSEcCtD
Galantamine—Syncope—Docetaxel—ovarian cancer	0.000503	0.000993	CcSEcCtD
Galantamine—Dysphagia—Doxorubicin—ovarian cancer	0.000502	0.000992	CcSEcCtD
Galantamine—Pollakiuria—Epirubicin—ovarian cancer	0.000501	0.00099	CcSEcCtD
Galantamine—Palpitations—Docetaxel—ovarian cancer	0.000495	0.000978	CcSEcCtD
Galantamine—Loss of consciousness—Docetaxel—ovarian cancer	0.000493	0.000973	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000492	0.000971	CcSEcCtD
Galantamine—Weight decreased—Epirubicin—ovarian cancer	0.000491	0.00097	CcSEcCtD
Galantamine—Hyperglycaemia—Epirubicin—ovarian cancer	0.000489	0.000967	CcSEcCtD
Galantamine—Cough—Docetaxel—ovarian cancer	0.000489	0.000966	CcSEcCtD
Galantamine—Insomnia—Paclitaxel—ovarian cancer	0.000488	0.000964	CcSEcCtD
Galantamine—Pneumonia—Epirubicin—ovarian cancer	0.000487	0.000961	CcSEcCtD
Galantamine—Convulsion—Docetaxel—ovarian cancer	0.000486	0.000959	CcSEcCtD
Galantamine—Paraesthesia—Paclitaxel—ovarian cancer	0.000485	0.000957	CcSEcCtD
Galantamine—Hypertension—Docetaxel—ovarian cancer	0.000484	0.000956	CcSEcCtD
Galantamine—Bronchitis—Doxorubicin—ovarian cancer	0.000483	0.000954	CcSEcCtD
Galantamine—Somnolence—Paclitaxel—ovarian cancer	0.00048	0.000948	CcSEcCtD
Galantamine—Arthralgia—Docetaxel—ovarian cancer	0.000477	0.000943	CcSEcCtD
Galantamine—Chest pain—Docetaxel—ovarian cancer	0.000477	0.000943	CcSEcCtD
Galantamine—Myalgia—Docetaxel—ovarian cancer	0.000477	0.000943	CcSEcCtD
Galantamine—Nausea—Vinorelbine—ovarian cancer	0.000477	0.000941	CcSEcCtD
Galantamine—Renal failure—Epirubicin—ovarian cancer	0.000476	0.000939	CcSEcCtD
Galantamine—Dyspepsia—Paclitaxel—ovarian cancer	0.000475	0.000938	CcSEcCtD
Galantamine—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000474	0.000937	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000474	0.000936	CcSEcCtD
Galantamine—Urinary tract infection—Epirubicin—ovarian cancer	0.00047	0.000929	CcSEcCtD
Galantamine—Decreased appetite—Paclitaxel—ovarian cancer	0.000469	0.000927	CcSEcCtD
Galantamine—Dry mouth—Docetaxel—ovarian cancer	0.000467	0.000922	CcSEcCtD
Galantamine—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000467	0.000922	CcSEcCtD
Galantamine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000466	0.00092	CcSEcCtD
Galantamine—Fatigue—Paclitaxel—ovarian cancer	0.000465	0.000919	CcSEcCtD
Galantamine—Pollakiuria—Doxorubicin—ovarian cancer	0.000464	0.000916	CcSEcCtD
Galantamine—Constipation—Paclitaxel—ovarian cancer	0.000462	0.000912	CcSEcCtD
Galantamine—Haematuria—Epirubicin—ovarian cancer	0.000461	0.000911	CcSEcCtD
Galantamine—Confusional state—Docetaxel—ovarian cancer	0.000461	0.000911	CcSEcCtD
Galantamine—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000458	0.000904	CcSEcCtD
Galantamine—Epistaxis—Epirubicin—ovarian cancer	0.000456	0.000901	CcSEcCtD
Galantamine—Weight decreased—Doxorubicin—ovarian cancer	0.000454	0.000897	CcSEcCtD
Galantamine—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000453	0.000895	CcSEcCtD
Galantamine—Pneumonia—Doxorubicin—ovarian cancer	0.00045	0.000889	CcSEcCtD
Galantamine—Shock—Docetaxel—ovarian cancer	0.00045	0.000889	CcSEcCtD
Galantamine—Nervous system disorder—Docetaxel—ovarian cancer	0.000449	0.000886	CcSEcCtD
Galantamine—Thrombocytopenia—Docetaxel—ovarian cancer	0.000448	0.000885	CcSEcCtD
Galantamine—Tachycardia—Docetaxel—ovarian cancer	0.000447	0.000882	CcSEcCtD
Galantamine—Feeling abnormal—Paclitaxel—ovarian cancer	0.000445	0.000878	CcSEcCtD
Galantamine—Skin disorder—Docetaxel—ovarian cancer	0.000444	0.000878	CcSEcCtD
Galantamine—Bradycardia—Epirubicin—ovarian cancer	0.000442	0.000873	CcSEcCtD
Galantamine—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000441	0.000872	CcSEcCtD
Galantamine—Renal failure—Doxorubicin—ovarian cancer	0.00044	0.000869	CcSEcCtD
Galantamine—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000439	0.000867	CcSEcCtD
Galantamine—Haemoglobin—Epirubicin—ovarian cancer	0.000437	0.000862	CcSEcCtD
Galantamine—Anorexia—Docetaxel—ovarian cancer	0.000436	0.000861	CcSEcCtD
Galantamine—Rhinitis—Epirubicin—ovarian cancer	0.000435	0.00086	CcSEcCtD
Galantamine—Urinary tract infection—Doxorubicin—ovarian cancer	0.000435	0.000859	CcSEcCtD
Galantamine—Haemorrhage—Epirubicin—ovarian cancer	0.000434	0.000858	CcSEcCtD
Galantamine—Hepatitis—Epirubicin—ovarian cancer	0.000434	0.000858	CcSEcCtD
Galantamine—Urinary tract disorder—Epirubicin—ovarian cancer	0.000429	0.000847	CcSEcCtD
Galantamine—Oedema peripheral—Epirubicin—ovarian cancer	0.000428	0.000845	CcSEcCtD
Galantamine—Hypotension—Docetaxel—ovarian cancer	0.000428	0.000844	CcSEcCtD
Galantamine—Haematuria—Doxorubicin—ovarian cancer	0.000427	0.000843	CcSEcCtD
Galantamine—Connective tissue disorder—Epirubicin—ovarian cancer	0.000427	0.000843	CcSEcCtD
Galantamine—Body temperature increased—Paclitaxel—ovarian cancer	0.000427	0.000843	CcSEcCtD
Galantamine—Abdominal pain—Paclitaxel—ovarian cancer	0.000427	0.000843	CcSEcCtD
Galantamine—Urethral disorder—Epirubicin—ovarian cancer	0.000426	0.000841	CcSEcCtD
Galantamine—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000423	0.000836	CcSEcCtD
Galantamine—Epistaxis—Doxorubicin—ovarian cancer	0.000422	0.000834	CcSEcCtD
Galantamine—Visual impairment—Epirubicin—ovarian cancer	0.000419	0.000827	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000417	0.000823	CcSEcCtD
Galantamine—Insomnia—Docetaxel—ovarian cancer	0.000414	0.000817	CcSEcCtD
Galantamine—Paraesthesia—Docetaxel—ovarian cancer	0.000411	0.000811	CcSEcCtD
Galantamine—Bradycardia—Doxorubicin—ovarian cancer	0.000409	0.000808	CcSEcCtD
Galantamine—Somnolence—Docetaxel—ovarian cancer	0.000407	0.000803	CcSEcCtD
Galantamine—Eye disorder—Epirubicin—ovarian cancer	0.000406	0.000802	CcSEcCtD
Galantamine—Tinnitus—Epirubicin—ovarian cancer	0.000405	0.0008	CcSEcCtD
Galantamine—Haemoglobin—Doxorubicin—ovarian cancer	0.000404	0.000798	CcSEcCtD
Galantamine—Flushing—Epirubicin—ovarian cancer	0.000403	0.000796	CcSEcCtD
Galantamine—Cardiac disorder—Epirubicin—ovarian cancer	0.000403	0.000796	CcSEcCtD
Galantamine—Rhinitis—Doxorubicin—ovarian cancer	0.000403	0.000796	CcSEcCtD
Galantamine—Dyspepsia—Docetaxel—ovarian cancer	0.000403	0.000795	CcSEcCtD
Galantamine—Haemorrhage—Doxorubicin—ovarian cancer	0.000402	0.000794	CcSEcCtD
Galantamine—Hepatitis—Doxorubicin—ovarian cancer	0.000402	0.000794	CcSEcCtD
Galantamine—Decreased appetite—Docetaxel—ovarian cancer	0.000398	0.000785	CcSEcCtD
Galantamine—Hypersensitivity—Paclitaxel—ovarian cancer	0.000398	0.000785	CcSEcCtD
Galantamine—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000397	0.000784	CcSEcCtD
Galantamine—Oedema peripheral—Doxorubicin—ovarian cancer	0.000396	0.000782	CcSEcCtD
Galantamine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000395	0.00078	CcSEcCtD
Galantamine—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000395	0.00078	CcSEcCtD
Galantamine—Fatigue—Docetaxel—ovarian cancer	0.000394	0.000779	CcSEcCtD
Galantamine—Angiopathy—Epirubicin—ovarian cancer	0.000394	0.000778	CcSEcCtD
Galantamine—Urethral disorder—Doxorubicin—ovarian cancer	0.000394	0.000778	CcSEcCtD
Galantamine—Immune system disorder—Epirubicin—ovarian cancer	0.000392	0.000775	CcSEcCtD
Galantamine—Constipation—Docetaxel—ovarian cancer	0.000391	0.000773	CcSEcCtD
Galantamine—Arrhythmia—Epirubicin—ovarian cancer	0.000388	0.000766	CcSEcCtD
Galantamine—Visual impairment—Doxorubicin—ovarian cancer	0.000387	0.000765	CcSEcCtD
Galantamine—Asthenia—Paclitaxel—ovarian cancer	0.000387	0.000765	CcSEcCtD
Galantamine—Mental disorder—Epirubicin—ovarian cancer	0.000381	0.000752	CcSEcCtD
Galantamine—Malnutrition—Epirubicin—ovarian cancer	0.000378	0.000747	CcSEcCtD
Galantamine—Feeling abnormal—Docetaxel—ovarian cancer	0.000377	0.000745	CcSEcCtD
Galantamine—Eye disorder—Doxorubicin—ovarian cancer	0.000376	0.000742	CcSEcCtD
Galantamine—Tinnitus—Doxorubicin—ovarian cancer	0.000375	0.00074	CcSEcCtD
Galantamine—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000374	0.000739	CcSEcCtD
Galantamine—Flushing—Doxorubicin—ovarian cancer	0.000373	0.000737	CcSEcCtD
Galantamine—Cardiac disorder—Doxorubicin—ovarian cancer	0.000373	0.000737	CcSEcCtD
Galantamine—Flatulence—Epirubicin—ovarian cancer	0.000373	0.000736	CcSEcCtD
Galantamine—Tension—Epirubicin—ovarian cancer	0.000371	0.000733	CcSEcCtD
Galantamine—Dysgeusia—Epirubicin—ovarian cancer	0.00037	0.000731	CcSEcCtD
Galantamine—Diarrhoea—Paclitaxel—ovarian cancer	0.000369	0.000729	CcSEcCtD
Galantamine—Nervousness—Epirubicin—ovarian cancer	0.000367	0.000725	CcSEcCtD
Galantamine—Back pain—Epirubicin—ovarian cancer	0.000366	0.000722	CcSEcCtD
Galantamine—Angiopathy—Doxorubicin—ovarian cancer	0.000365	0.00072	CcSEcCtD
Galantamine—Muscle spasms—Epirubicin—ovarian cancer	0.000364	0.000718	CcSEcCtD
Galantamine—Immune system disorder—Doxorubicin—ovarian cancer	0.000363	0.000717	CcSEcCtD
Galantamine—Body temperature increased—Docetaxel—ovarian cancer	0.000362	0.000714	CcSEcCtD
Galantamine—Abdominal pain—Docetaxel—ovarian cancer	0.000362	0.000714	CcSEcCtD
Galantamine—Arrhythmia—Doxorubicin—ovarian cancer	0.000359	0.000709	CcSEcCtD
Galantamine—Dizziness—Paclitaxel—ovarian cancer	0.000357	0.000705	CcSEcCtD
Galantamine—Vision blurred—Epirubicin—ovarian cancer	0.000356	0.000704	CcSEcCtD
Galantamine—Mental disorder—Doxorubicin—ovarian cancer	0.000352	0.000695	CcSEcCtD
Galantamine—Ill-defined disorder—Epirubicin—ovarian cancer	0.000351	0.000693	CcSEcCtD
Galantamine—Malnutrition—Doxorubicin—ovarian cancer	0.00035	0.000691	CcSEcCtD
Galantamine—Anaemia—Epirubicin—ovarian cancer	0.000349	0.00069	CcSEcCtD
Galantamine—Agitation—Epirubicin—ovarian cancer	0.000347	0.000686	CcSEcCtD
Galantamine—Flatulence—Doxorubicin—ovarian cancer	0.000345	0.000681	CcSEcCtD
Galantamine—Tension—Doxorubicin—ovarian cancer	0.000343	0.000678	CcSEcCtD
Galantamine—Vomiting—Paclitaxel—ovarian cancer	0.000343	0.000678	CcSEcCtD
Galantamine—Dysgeusia—Doxorubicin—ovarian cancer	0.000343	0.000677	CcSEcCtD
Galantamine—Malaise—Epirubicin—ovarian cancer	0.000341	0.000673	CcSEcCtD
Galantamine—Rash—Paclitaxel—ovarian cancer	0.00034	0.000672	CcSEcCtD
Galantamine—Dermatitis—Paclitaxel—ovarian cancer	0.00034	0.000672	CcSEcCtD
Galantamine—Nervousness—Doxorubicin—ovarian cancer	0.00034	0.000671	CcSEcCtD
Galantamine—Vertigo—Epirubicin—ovarian cancer	0.00034	0.000671	CcSEcCtD
Galantamine—Syncope—Epirubicin—ovarian cancer	0.000339	0.00067	CcSEcCtD
Galantamine—Back pain—Doxorubicin—ovarian cancer	0.000338	0.000668	CcSEcCtD
Galantamine—Headache—Paclitaxel—ovarian cancer	0.000338	0.000668	CcSEcCtD
Galantamine—Hypersensitivity—Docetaxel—ovarian cancer	0.000337	0.000666	CcSEcCtD
Galantamine—Muscle spasms—Doxorubicin—ovarian cancer	0.000336	0.000664	CcSEcCtD
Galantamine—Palpitations—Epirubicin—ovarian cancer	0.000334	0.00066	CcSEcCtD
Galantamine—Loss of consciousness—Epirubicin—ovarian cancer	0.000332	0.000656	CcSEcCtD
Galantamine—Cough—Epirubicin—ovarian cancer	0.00033	0.000652	CcSEcCtD
Galantamine—Vision blurred—Doxorubicin—ovarian cancer	0.00033	0.000651	CcSEcCtD
Galantamine—Asthenia—Docetaxel—ovarian cancer	0.000328	0.000648	CcSEcCtD
Galantamine—Convulsion—Epirubicin—ovarian cancer	0.000328	0.000647	CcSEcCtD
Galantamine—Hypertension—Epirubicin—ovarian cancer	0.000326	0.000645	CcSEcCtD
Galantamine—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000325	0.000641	CcSEcCtD
Galantamine—Anaemia—Doxorubicin—ovarian cancer	0.000323	0.000639	CcSEcCtD
Galantamine—Myalgia—Epirubicin—ovarian cancer	0.000322	0.000636	CcSEcCtD
Galantamine—Arthralgia—Epirubicin—ovarian cancer	0.000322	0.000636	CcSEcCtD
Galantamine—Chest pain—Epirubicin—ovarian cancer	0.000322	0.000636	CcSEcCtD
Galantamine—Agitation—Doxorubicin—ovarian cancer	0.000322	0.000635	CcSEcCtD
Galantamine—Anxiety—Epirubicin—ovarian cancer	0.000321	0.000634	CcSEcCtD
Galantamine—Nausea—Paclitaxel—ovarian cancer	0.000321	0.000633	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.00032	0.000631	CcSEcCtD
Galantamine—Discomfort—Epirubicin—ovarian cancer	0.000318	0.000628	CcSEcCtD
Galantamine—Malaise—Doxorubicin—ovarian cancer	0.000315	0.000623	CcSEcCtD
Galantamine—Dry mouth—Epirubicin—ovarian cancer	0.000315	0.000622	CcSEcCtD
Galantamine—Vertigo—Doxorubicin—ovarian cancer	0.000314	0.000621	CcSEcCtD
Galantamine—Syncope—Doxorubicin—ovarian cancer	0.000314	0.00062	CcSEcCtD
Galantamine—Diarrhoea—Docetaxel—ovarian cancer	0.000313	0.000618	CcSEcCtD
Galantamine—Confusional state—Epirubicin—ovarian cancer	0.000311	0.000615	CcSEcCtD
Galantamine—Palpitations—Doxorubicin—ovarian cancer	0.000309	0.000611	CcSEcCtD
Galantamine—Loss of consciousness—Doxorubicin—ovarian cancer	0.000307	0.000607	CcSEcCtD
Galantamine—Cough—Doxorubicin—ovarian cancer	0.000305	0.000603	CcSEcCtD
Galantamine—Shock—Epirubicin—ovarian cancer	0.000304	0.0006	CcSEcCtD
Galantamine—Convulsion—Doxorubicin—ovarian cancer	0.000303	0.000599	CcSEcCtD
Galantamine—Nervous system disorder—Epirubicin—ovarian cancer	0.000303	0.000598	CcSEcCtD
Galantamine—Dizziness—Docetaxel—ovarian cancer	0.000303	0.000597	CcSEcCtD
Galantamine—Thrombocytopenia—Epirubicin—ovarian cancer	0.000302	0.000597	CcSEcCtD
Galantamine—Hypertension—Doxorubicin—ovarian cancer	0.000302	0.000597	CcSEcCtD
Galantamine—Tachycardia—Epirubicin—ovarian cancer	0.000301	0.000595	CcSEcCtD
Galantamine—Skin disorder—Epirubicin—ovarian cancer	0.0003	0.000592	CcSEcCtD
Galantamine—Hyperhidrosis—Epirubicin—ovarian cancer	0.000298	0.000589	CcSEcCtD
Galantamine—Chest pain—Doxorubicin—ovarian cancer	0.000298	0.000588	CcSEcCtD
Galantamine—Arthralgia—Doxorubicin—ovarian cancer	0.000298	0.000588	CcSEcCtD
Galantamine—Myalgia—Doxorubicin—ovarian cancer	0.000298	0.000588	CcSEcCtD
Galantamine—Anxiety—Doxorubicin—ovarian cancer	0.000297	0.000586	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000296	0.000584	CcSEcCtD
Galantamine—Discomfort—Doxorubicin—ovarian cancer	0.000294	0.000581	CcSEcCtD
Galantamine—Anorexia—Epirubicin—ovarian cancer	0.000294	0.000581	CcSEcCtD
Galantamine—Dry mouth—Doxorubicin—ovarian cancer	0.000291	0.000575	CcSEcCtD
Galantamine—Vomiting—Docetaxel—ovarian cancer	0.000291	0.000574	CcSEcCtD
Galantamine—Rash—Docetaxel—ovarian cancer	0.000288	0.00057	CcSEcCtD
Galantamine—Hypotension—Epirubicin—ovarian cancer	0.000288	0.000569	CcSEcCtD
Galantamine—Dermatitis—Docetaxel—ovarian cancer	0.000288	0.000569	CcSEcCtD
Galantamine—Confusional state—Doxorubicin—ovarian cancer	0.000288	0.000569	CcSEcCtD
Galantamine—Headache—Docetaxel—ovarian cancer	0.000287	0.000566	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000281	0.000555	CcSEcCtD
Galantamine—Shock—Doxorubicin—ovarian cancer	0.000281	0.000555	CcSEcCtD
Galantamine—Nervous system disorder—Doxorubicin—ovarian cancer	0.00028	0.000553	CcSEcCtD
Galantamine—Thrombocytopenia—Doxorubicin—ovarian cancer	0.00028	0.000552	CcSEcCtD
Galantamine—Insomnia—Epirubicin—ovarian cancer	0.000279	0.000551	CcSEcCtD
Galantamine—Tachycardia—Doxorubicin—ovarian cancer	0.000279	0.00055	CcSEcCtD
Galantamine—Skin disorder—Doxorubicin—ovarian cancer	0.000277	0.000548	CcSEcCtD
Galantamine—Paraesthesia—Epirubicin—ovarian cancer	0.000277	0.000547	CcSEcCtD
Galantamine—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000276	0.000545	CcSEcCtD
Galantamine—Somnolence—Epirubicin—ovarian cancer	0.000274	0.000542	CcSEcCtD
Galantamine—Anorexia—Doxorubicin—ovarian cancer	0.000272	0.000538	CcSEcCtD
Galantamine—Nausea—Docetaxel—ovarian cancer	0.000272	0.000537	CcSEcCtD
Galantamine—Dyspepsia—Epirubicin—ovarian cancer	0.000272	0.000536	CcSEcCtD
Galantamine—Decreased appetite—Epirubicin—ovarian cancer	0.000268	0.00053	CcSEcCtD
Galantamine—Hypotension—Doxorubicin—ovarian cancer	0.000267	0.000527	CcSEcCtD
Galantamine—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000266	0.000526	CcSEcCtD
Galantamine—Fatigue—Epirubicin—ovarian cancer	0.000266	0.000525	CcSEcCtD
Galantamine—Constipation—Epirubicin—ovarian cancer	0.000264	0.000521	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.00026	0.000514	CcSEcCtD
Galantamine—Insomnia—Doxorubicin—ovarian cancer	0.000258	0.00051	CcSEcCtD
Galantamine—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000257	0.00181	CbGpPWpGaD
Galantamine—Paraesthesia—Doxorubicin—ovarian cancer	0.000256	0.000506	CcSEcCtD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—CXCL8—ovarian cancer	0.000256	0.00181	CbGpPWpGaD
Galantamine—Feeling abnormal—Epirubicin—ovarian cancer	0.000254	0.000502	CcSEcCtD
Galantamine—Somnolence—Doxorubicin—ovarian cancer	0.000254	0.000501	CcSEcCtD
Galantamine—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000252	0.000498	CcSEcCtD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	0.000252	0.00178	CbGpPWpGaD
Galantamine—Dyspepsia—Doxorubicin—ovarian cancer	0.000251	0.000496	CcSEcCtD
Galantamine—Decreased appetite—Doxorubicin—ovarian cancer	0.000248	0.00049	CcSEcCtD
Galantamine—CHRNB3—Transmission across Chemical Synapses—HRAS—ovarian cancer	0.000247	0.00175	CbGpPWpGaD
Galantamine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000247	0.000487	CcSEcCtD
Galantamine—Fatigue—Doxorubicin—ovarian cancer	0.000246	0.000486	CcSEcCtD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—CASP3—ovarian cancer	0.000245	0.00173	CbGpPWpGaD
Galantamine—Constipation—Doxorubicin—ovarian cancer	0.000244	0.000482	CcSEcCtD
Galantamine—Abdominal pain—Epirubicin—ovarian cancer	0.000244	0.000482	CcSEcCtD
Galantamine—Body temperature increased—Epirubicin—ovarian cancer	0.000244	0.000482	CcSEcCtD
Galantamine—CHRNB2—Circadian rythm related genes—PTEN—ovarian cancer	0.000238	0.00169	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	0.000236	0.00167	CbGpPWpGaD
Galantamine—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	0.000236	0.00167	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—CTNNB1—ovarian cancer	0.000236	0.00167	CbGpPWpGaD
Galantamine—CHRNB3—Neuronal System—MAPK1—ovarian cancer	0.000236	0.00167	CbGpPWpGaD
Galantamine—Feeling abnormal—Doxorubicin—ovarian cancer	0.000235	0.000465	CcSEcCtD
Galantamine—CHRNA5—Transmission across Chemical Synapses—HRAS—ovarian cancer	0.000234	0.00166	CbGpPWpGaD
Galantamine—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000233	0.000461	CcSEcCtD
Galantamine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.000232	0.00164	CbGpPWpGaD
Galantamine—Hypersensitivity—Epirubicin—ovarian cancer	0.000227	0.000449	CcSEcCtD
Galantamine—Abdominal pain—Doxorubicin—ovarian cancer	0.000226	0.000446	CcSEcCtD
Galantamine—Body temperature increased—Doxorubicin—ovarian cancer	0.000226	0.000446	CcSEcCtD
Galantamine—CHRNA5—Neuronal System—MAPK1—ovarian cancer	0.000224	0.00158	CbGpPWpGaD
Galantamine—CHRNG—Transmission across Chemical Synapses—HRAS—ovarian cancer	0.000223	0.00158	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—CXCL8—ovarian cancer	0.000222	0.00157	CbGpPWpGaD
Galantamine—Asthenia—Epirubicin—ovarian cancer	0.000221	0.000437	CcSEcCtD
Galantamine—CHRNA6—Transmission across Chemical Synapses—MAPK1—ovarian cancer	0.000221	0.00156	CbGpPWpGaD
Galantamine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.000221	0.00156	CbGpPWpGaD
Galantamine—CHRNA9—Neuronal System—HRAS—ovarian cancer	0.000217	0.00153	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—MAPK3—ovarian cancer	0.000216	0.00153	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	0.000214	0.00151	CbGpPWpGaD
Galantamine—CHRNG—Neuronal System—MAPK1—ovarian cancer	0.000213	0.00151	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—CASP3—ovarian cancer	0.000212	0.0015	CbGpPWpGaD
Galantamine—Diarrhoea—Epirubicin—ovarian cancer	0.000211	0.000417	CcSEcCtD
Galantamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000211	0.00149	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000211	0.00149	CbGpPWpGaD
Galantamine—Hypersensitivity—Doxorubicin—ovarian cancer	0.00021	0.000415	CcSEcCtD
Galantamine—CYP3A4—Tryptophan metabolism—CYP1B1—ovarian cancer	0.00021	0.00149	CbGpPWpGaD
Galantamine—CHRNE—Transmission across Chemical Synapses—HRAS—ovarian cancer	0.00021	0.00148	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—INHA—ovarian cancer	0.000208	0.00147	CbGpPWpGaD
Galantamine—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	0.000208	0.00147	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—VEGFA—ovarian cancer	0.000208	0.00147	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	0.000207	0.00146	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	0.000207	0.00146	CbGpPWpGaD
Galantamine—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	0.000206	0.00146	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—MAPK1—ovarian cancer	0.000205	0.00145	CbGpPWpGaD
Galantamine—Asthenia—Doxorubicin—ovarian cancer	0.000205	0.000405	CcSEcCtD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—CTNNB1—ovarian cancer	0.000205	0.00145	CbGpPWpGaD
Galantamine—Dizziness—Epirubicin—ovarian cancer	0.000204	0.000403	CcSEcCtD
Galantamine—CHRNB4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	0.000204	0.00144	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	0.000203	0.00144	CbGpPWpGaD
Galantamine—CHRNE—Neuronal System—MAPK1—ovarian cancer	0.0002	0.00142	CbGpPWpGaD
Galantamine—Vomiting—Epirubicin—ovarian cancer	0.000196	0.000387	CcSEcCtD
Galantamine—Diarrhoea—Doxorubicin—ovarian cancer	0.000195	0.000386	CcSEcCtD
Galantamine—CHRNB2—Transmission across Chemical Synapses—MAPK1—ovarian cancer	0.000195	0.00138	CbGpPWpGaD
Galantamine—Rash—Epirubicin—ovarian cancer	0.000195	0.000384	CcSEcCtD
Galantamine—Dermatitis—Epirubicin—ovarian cancer	0.000194	0.000384	CcSEcCtD
Galantamine—ACHE—Peptide hormone metabolism—CTNNB1—ovarian cancer	0.000194	0.00137	CbGpPWpGaD
Galantamine—ACHE—Phospholipid metabolism—PIK3CG—ovarian cancer	0.000193	0.00137	CbGpPWpGaD
Galantamine—Headache—Epirubicin—ovarian cancer	0.000193	0.000382	CcSEcCtD
Galantamine—CHRNB3—Neuronal System—HRAS—ovarian cancer	0.000189	0.00134	CbGpPWpGaD
Galantamine—Dizziness—Doxorubicin—ovarian cancer	0.000189	0.000373	CcSEcCtD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000188	0.00133	CbGpPWpGaD
Galantamine—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	0.000186	0.00132	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—INHA—ovarian cancer	0.000186	0.00131	CbGpPWpGaD
Galantamine—Nausea—Epirubicin—ovarian cancer	0.000183	0.000362	CcSEcCtD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—IL6—ovarian cancer	0.000182	0.00129	CbGpPWpGaD
Galantamine—Vomiting—Doxorubicin—ovarian cancer	0.000182	0.000359	CcSEcCtD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—CXCL8—ovarian cancer	0.000181	0.00128	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—VEGFA—ovarian cancer	0.00018	0.00127	CbGpPWpGaD
Galantamine—Rash—Doxorubicin—ovarian cancer	0.00018	0.000356	CcSEcCtD
Galantamine—Dermatitis—Doxorubicin—ovarian cancer	0.00018	0.000355	CcSEcCtD
Galantamine—CHRNA5—Neuronal System—HRAS—ovarian cancer	0.000179	0.00127	CbGpPWpGaD
Galantamine—Headache—Doxorubicin—ovarian cancer	0.000179	0.000353	CcSEcCtD
Galantamine—CHRNA6—Transmission across Chemical Synapses—HRAS—ovarian cancer	0.000177	0.00125	CbGpPWpGaD
Galantamine—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	0.000177	0.00125	CbGpPWpGaD
Galantamine—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	0.000175	0.00124	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—CASP3—ovarian cancer	0.000173	0.00122	CbGpPWpGaD
Galantamine—BCHE—Peptide hormone metabolism—CTNNB1—ovarian cancer	0.000173	0.00122	CbGpPWpGaD
Galantamine—BCHE—Phospholipid metabolism—PIK3CG—ovarian cancer	0.000172	0.00122	CbGpPWpGaD
Galantamine—CHRNG—Neuronal System—HRAS—ovarian cancer	0.000171	0.00121	CbGpPWpGaD
Galantamine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.00017	0.0012	CbGpPWpGaD
Galantamine—ACHE—Phospholipid metabolism—PIK3CD—ovarian cancer	0.00017	0.0012	CbGpPWpGaD
Galantamine—Nausea—Doxorubicin—ovarian cancer	0.00017	0.000335	CcSEcCtD
Galantamine—CHRNA6—Neuronal System—MAPK1—ovarian cancer	0.000169	0.0012	CbGpPWpGaD
Galantamine—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000168	0.00119	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—CTNNB1—ovarian cancer	0.000167	0.00118	CbGpPWpGaD
Galantamine—ACHE—Metabolism—NME2—ovarian cancer	0.000167	0.00118	CbGpPWpGaD
Galantamine—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	0.000166	0.00118	CbGpPWpGaD
Galantamine—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	0.000165	0.00117	CbGpPWpGaD
Galantamine—CHRNB4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	0.000164	0.00116	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—TP53—ovarian cancer	0.000163	0.00115	CbGpPWpGaD
Galantamine—CHRNE—Neuronal System—HRAS—ovarian cancer	0.000161	0.00114	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—IL6—ovarian cancer	0.000158	0.00112	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	0.000158	0.00111	CbGpPWpGaD
Galantamine—CHRNB2—Transmission across Chemical Synapses—HRAS—ovarian cancer	0.000156	0.0011	CbGpPWpGaD
Galantamine—CHRND—Transmission across Chemical Synapses—MAPK1—ovarian cancer	0.000155	0.00109	CbGpPWpGaD
Galantamine—CHRNB4—Transmission across Chemical Synapses—MAPK1—ovarian cancer	0.000153	0.00108	CbGpPWpGaD
Galantamine—BCHE—Phospholipid metabolism—PIK3CD—ovarian cancer	0.000152	0.00107	CbGpPWpGaD
Galantamine—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	0.00015	0.00106	CbGpPWpGaD
Galantamine—CHRNB2—Neuronal System—MAPK1—ovarian cancer	0.000149	0.00105	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	0.000149	0.00105	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—IL6—ovarian cancer	0.000149	0.00105	CbGpPWpGaD
Galantamine—BCHE—Metabolism—NME2—ovarian cancer	0.000149	0.00105	CbGpPWpGaD
Galantamine—ACHE—Phospholipid metabolism—PIK3CB—ovarian cancer	0.000148	0.00105	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—VEGFA—ovarian cancer	0.000147	0.00104	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—TUBB3—ovarian cancer	0.000147	0.00104	CbGpPWpGaD
Galantamine—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	0.000144	0.00102	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—IL6—ovarian cancer	0.000144	0.00102	CbGpPWpGaD
Galantamine—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	0.000142	0.001	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	0.000141	0.000998	CbGpPWpGaD
Galantamine—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	0.000141	0.000993	CbGpPWpGaD
Galantamine—CHRNA3—Transmission across Chemical Synapses—MAPK1—ovarian cancer	0.00014	0.000991	CbGpPWpGaD
Galantamine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000138	0.000974	CbGpPWpGaD
Galantamine—CHRNA6—Neuronal System—HRAS—ovarian cancer	0.000136	0.000961	CbGpPWpGaD
Galantamine—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	0.000134	0.000944	CbGpPWpGaD
Galantamine—CHRNA7—Transmission across Chemical Synapses—MAPK1—ovarian cancer	0.000133	0.00094	CbGpPWpGaD
Galantamine—BCHE—Phospholipid metabolism—PIK3CB—ovarian cancer	0.000132	0.000934	CbGpPWpGaD
Galantamine—CHRNA1—Transmission across Chemical Synapses—MAPK1—ovarian cancer	0.000132	0.00093	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—TUBB3—ovarian cancer	0.000131	0.000925	CbGpPWpGaD
Galantamine—ACHE—Phospholipid metabolism—PTEN—ovarian cancer	0.000128	0.000905	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	0.000126	0.000891	CbGpPWpGaD
Galantamine—CHRNA2—Transmission across Chemical Synapses—MAPK1—ovarian cancer	0.000125	0.000884	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—IL6—ovarian cancer	0.000125	0.000881	CbGpPWpGaD
Galantamine—CHRND—Transmission across Chemical Synapses—HRAS—ovarian cancer	0.000124	0.000878	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—ATF3—ovarian cancer	0.000124	0.000875	CbGpPWpGaD
Galantamine—CHRNB4—Transmission across Chemical Synapses—HRAS—ovarian cancer	0.000123	0.000869	CbGpPWpGaD
Galantamine—CHRNB2—Neuronal System—HRAS—ovarian cancer	0.00012	0.000846	CbGpPWpGaD
Galantamine—CHRND—Neuronal System—MAPK1—ovarian cancer	0.000119	0.000838	CbGpPWpGaD
Galantamine—CHRNB4—Neuronal System—MAPK1—ovarian cancer	0.000117	0.00083	CbGpPWpGaD
Galantamine—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	0.000116	0.000818	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	0.000116	0.000818	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	0.000115	0.000814	CbGpPWpGaD
Galantamine—BCHE—Phospholipid metabolism—PTEN—ovarian cancer	0.000114	0.000807	CbGpPWpGaD
Galantamine—CHRNA3—Transmission across Chemical Synapses—HRAS—ovarian cancer	0.000113	0.000795	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—CYP1B1—ovarian cancer	0.000112	0.000792	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—CYP1B1—ovarian cancer	0.00011	0.000781	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—ATF3—ovarian cancer	0.00011	0.000781	CbGpPWpGaD
Galantamine—CHRNA4—Transmission across Chemical Synapses—MAPK1—ovarian cancer	0.000108	0.000766	CbGpPWpGaD
Galantamine—CHRNA3—Neuronal System—MAPK1—ovarian cancer	0.000107	0.000759	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CYTB—ovarian cancer	0.000107	0.000758	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	0.000107	0.000758	CbGpPWpGaD
Galantamine—CHRNA7—Transmission across Chemical Synapses—HRAS—ovarian cancer	0.000107	0.000755	CbGpPWpGaD
Galantamine—CHRNA1—Transmission across Chemical Synapses—HRAS—ovarian cancer	0.000106	0.000747	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	0.000105	0.000743	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	0.000105	0.000741	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	0.000103	0.000726	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	0.000102	0.000723	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—MAPK1—ovarian cancer	0.000102	0.00072	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—IL6—ovarian cancer	0.000102	0.000718	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	0.000101	0.000716	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—MAPK1—ovarian cancer	0.000101	0.000713	CbGpPWpGaD
Galantamine—CHRNA2—Transmission across Chemical Synapses—HRAS—ovarian cancer	0.0001	0.00071	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	9.87e-05	0.000698	CbGpPWpGaD
Galantamine—CHRNA2—Neuronal System—MAPK1—ovarian cancer	9.58e-05	0.000677	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CYTB—ovarian cancer	9.57e-05	0.000677	CbGpPWpGaD
Galantamine—CHRND—Neuronal System—HRAS—ovarian cancer	9.52e-05	0.000673	CbGpPWpGaD
Galantamine—CHRNB4—Neuronal System—HRAS—ovarian cancer	9.43e-05	0.000666	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PPP1CC—ovarian cancer	9.38e-05	0.000663	CbGpPWpGaD
Galantamine—ACHE—Metabolism—BRIP1—ovarian cancer	9.38e-05	0.000663	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	9.36e-05	0.000661	CbGpPWpGaD
Galantamine—ACHE—Phospholipid metabolism—PIK3CA—ovarian cancer	9.03e-05	0.000638	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	8.92e-05	0.00063	CbGpPWpGaD
Galantamine—CHRNA4—Transmission across Chemical Synapses—HRAS—ovarian cancer	8.7e-05	0.000615	CbGpPWpGaD
Galantamine—CHRNA3—Neuronal System—HRAS—ovarian cancer	8.62e-05	0.000609	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	8.43e-05	0.000596	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PPP1CC—ovarian cancer	8.37e-05	0.000591	CbGpPWpGaD
Galantamine—BCHE—Metabolism—BRIP1—ovarian cancer	8.37e-05	0.000591	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—MAPK1—ovarian cancer	8.31e-05	0.000587	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	8.2e-05	0.00058	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—HRAS—ovarian cancer	8.18e-05	0.000578	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—HRAS—ovarian cancer	8.1e-05	0.000572	CbGpPWpGaD
Galantamine—BCHE—Phospholipid metabolism—PIK3CA—ovarian cancer	8.06e-05	0.000569	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	8.02e-05	0.000567	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	8.02e-05	0.000567	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—MAPK1—ovarian cancer	7.73e-05	0.000547	CbGpPWpGaD
Galantamine—CHRNA2—Neuronal System—HRAS—ovarian cancer	7.69e-05	0.000544	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	7.58e-05	0.000536	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	7.32e-05	0.000518	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	7.22e-05	0.00051	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	6.96e-05	0.000492	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—MAPK1—ovarian cancer	6.9e-05	0.000488	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	6.83e-05	0.000483	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—NME2—ovarian cancer	6.83e-05	0.000483	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	6.74e-05	0.000476	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—HRAS—ovarian cancer	6.67e-05	0.000471	CbGpPWpGaD
Galantamine—ACHE—Metabolism—YAP1—ovarian cancer	6.29e-05	0.000445	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	6.23e-05	0.00044	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—HRAS—ovarian cancer	6.21e-05	0.000439	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	6.1e-05	0.000431	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—MAPK1—ovarian cancer	5.93e-05	0.000419	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	5.69e-05	0.000402	CbGpPWpGaD
Galantamine—BCHE—Metabolism—YAP1—ovarian cancer	5.61e-05	0.000397	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	5.55e-05	0.000392	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—HRAS—ovarian cancer	5.54e-05	0.000392	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	5.47e-05	0.000387	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—MAPK1—ovarian cancer	5.29e-05	0.000374	CbGpPWpGaD
Galantamine—ACHE—Metabolism—FASN—ovarian cancer	5.13e-05	0.000362	CbGpPWpGaD
Galantamine—ACHE—Metabolism—SLC5A5—ovarian cancer	5.04e-05	0.000356	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	4.88e-05	0.000345	CbGpPWpGaD
Galantamine—ACHE—Metabolism—SLC2A1—ovarian cancer	4.87e-05	0.000344	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	4.77e-05	0.000337	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—MMP2—ovarian cancer	4.77e-05	0.000337	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—HRAS—ovarian cancer	4.76e-05	0.000336	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CYP1B1—ovarian cancer	4.67e-05	0.00033	CbGpPWpGaD
Galantamine—BCHE—Metabolism—FASN—ovarian cancer	4.57e-05	0.000323	CbGpPWpGaD
Galantamine—BCHE—Metabolism—SLC5A5—ovarian cancer	4.5e-05	0.000318	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—NME2—ovarian cancer	4.47e-05	0.000316	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYTB—ovarian cancer	4.4e-05	0.000311	CbGpPWpGaD
Galantamine—BCHE—Metabolism—SLC2A1—ovarian cancer	4.35e-05	0.000307	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	4.26e-05	0.000301	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—MMP2—ovarian cancer	4.25e-05	0.000301	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—HRAS—ovarian cancer	4.24e-05	0.0003	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CYP1B1—ovarian cancer	4.17e-05	0.000294	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PPP2R1A—ovarian cancer	4.14e-05	0.000293	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.12e-05	0.000291	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—CXCL8—ovarian cancer	3.96e-05	0.00028	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—BRIP1—ovarian cancer	3.85e-05	0.000272	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PPP1CC—ovarian cancer	3.85e-05	0.000272	CbGpPWpGaD
Galantamine—ACHE—Metabolism—ABCB1—ovarian cancer	3.85e-05	0.000272	CbGpPWpGaD
Galantamine—ACHE—Metabolism—TYMS—ovarian cancer	3.78e-05	0.000267	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PPP2R1A—ovarian cancer	3.7e-05	0.000261	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.68e-05	0.00026	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—CTNNB1—ovarian cancer	3.65e-05	0.000258	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—CXCL8—ovarian cancer	3.53e-05	0.00025	CbGpPWpGaD
Galantamine—BCHE—Metabolism—ABCB1—ovarian cancer	3.43e-05	0.000242	CbGpPWpGaD
Galantamine—BCHE—Metabolism—TYMS—ovarian cancer	3.37e-05	0.000238	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—CTNNB1—ovarian cancer	3.26e-05	0.00023	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CAV1—ovarian cancer	3.04e-05	0.000215	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.91e-05	0.000206	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYTB—ovarian cancer	2.88e-05	0.000203	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PIK3CG—ovarian cancer	2.77e-05	0.000196	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CAV1—ovarian cancer	2.72e-05	0.000192	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.59e-05	0.000183	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—YAP1—ovarian cancer	2.58e-05	0.000182	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PPP1CC—ovarian cancer	2.52e-05	0.000178	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—BRIP1—ovarian cancer	2.52e-05	0.000178	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PIK3CG—ovarian cancer	2.47e-05	0.000175	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PIK3CD—ovarian cancer	2.44e-05	0.000172	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PIK3CD—ovarian cancer	2.17e-05	0.000154	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PIK3CB—ovarian cancer	2.12e-05	0.00015	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—FASN—ovarian cancer	2.1e-05	0.000149	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—SLC5A5—ovarian cancer	2.07e-05	0.000146	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—SLC2A1—ovarian cancer	2e-05	0.000141	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP1B1—ovarian cancer	1.92e-05	0.000135	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PIK3CB—ovarian cancer	1.9e-05	0.000134	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PTEN—ovarian cancer	1.84e-05	0.00013	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	1.7e-05	0.00012	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—YAP1—ovarian cancer	1.69e-05	0.000119	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PTEN—ovarian cancer	1.64e-05	0.000116	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ABCB1—ovarian cancer	1.58e-05	0.000111	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—TYMS—ovarian cancer	1.55e-05	0.000109	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—FASN—ovarian cancer	1.38e-05	9.72e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—SLC5A5—ovarian cancer	1.35e-05	9.56e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—SLC2A1—ovarian cancer	1.31e-05	9.23e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PIK3CA—ovarian cancer	1.3e-05	9.15e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP1B1—ovarian cancer	1.25e-05	8.85e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CAV1—ovarian cancer	1.25e-05	8.82e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PIK3CA—ovarian cancer	1.16e-05	8.17e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PIK3CG—ovarian cancer	1.14e-05	8.04e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.11e-05	7.85e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—AKT1—ovarian cancer	1.06e-05	7.48e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.03e-05	7.29e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—TYMS—ovarian cancer	1.01e-05	7.16e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1e-05	7.07e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—AKT1—ovarian cancer	9.44e-06	6.67e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PIK3CB—ovarian cancer	8.71e-06	6.16e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CAV1—ovarian cancer	8.16e-06	5.77e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PTEN—ovarian cancer	7.53e-06	5.32e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PIK3CG—ovarian cancer	7.43e-06	5.25e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PIK3CD—ovarian cancer	6.54e-06	4.62e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PIK3CB—ovarian cancer	5.7e-06	4.03e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PIK3CA—ovarian cancer	5.31e-06	3.75e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PTEN—ovarian cancer	4.92e-06	3.48e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—AKT1—ovarian cancer	4.34e-06	3.07e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PIK3CA—ovarian cancer	3.47e-06	2.45e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—AKT1—ovarian cancer	2.84e-06	2.01e-05	CbGpPWpGaD
